AstraZeneca's BAXDROSTAT Trial Meets Primary Endpoint
Ticker: AZN · Form: 6-K · Filed: Oct 7, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 9 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial-success, drug-development, pharmaceuticals
Related Tickers: AZN
TL;DR
AZN's BAXDROSTAT trial hits primary endpoint, good news for Cushing's syndrome patients.
AI Summary
AstraZeneca PLC announced on October 7, 2025, that its BAXDROSTAT Phase 3 trial, BAX24, met its primary endpoint. The trial evaluated BAXDROSTAT for the treatment of hypercortisolism in adults with Cushing's syndrome.
Why It Matters
This positive trial result is a significant step towards potential regulatory approval for BAXDROSTAT, offering a new treatment option for patients with Cushing's syndrome.
Risk Assessment
Risk Level: low — The filing is an informational report of a successful clinical trial outcome, which is generally positive news and does not introduce new immediate risks.
Key Players & Entities
- AstraZeneca PLC (company) — Registrant
- BAXDROSTAT (drug) — Investigational drug
- BAX24 (trial) — Phase 3 clinical trial name
- Cushing's syndrome (disease) — Condition being treated
- October 7, 2025 (date) — Filing date and announcement date
FAQ
What is the primary endpoint of the BAX24 Phase 3 trial?
The filing states that the BAX24 Phase 3 trial met its primary endpoint, but does not specify what that endpoint is.
What condition is BAXDROSTAT intended to treat?
BAXDROSTAT is being evaluated for the treatment of hypercortisolism in adults with Cushing's syndrome.
When was this information filed with the SEC?
This Form 6-K was filed on October 7, 2025.
What is AstraZeneca's central index key?
AstraZeneca PLC's central index key is 0000901832.
What is the business address of AstraZeneca PLC?
The business address is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Filing Stats: 2,352 words · 9 min read · ~8 pages · Grade level 11 · Accepted 2025-10-07 06:30:06
Filing Documents
- a2843c.htm (6-K) — 49KB
- 0001654954-25-011529.txt ( ) — 50KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     AstraZeneca PLC     Date: 07 October 2025     By: /s/ Matthew Bowden   Name: Matthew Bowden   Title: Company Secretary